Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adipogenin (ADIG)
- Target
- ADIG
- Molecular classification
- Other (adipocyte-enriched transmembrane protein)
01
Overview
Adipogenin (ADIG), also known as Small adipocyte factor 1 (SMAF1), is a small (~10 kDa) adipocyte-enriched transmembrane protein. It is predominantly expressed in adipocytes and is induced during adipocyte differentiation (adipogenesis). ADIG appears to regulate adipogenesis and adipocyte function, especially by modulating leptin secretion—it is required for normal formation of adipose tissue and maintenance of fat mass. Loss of ADIG in mouse models impairs adipogenesis, reduces fat mass accumulation (especially under high-fat diet conditions), and decreases leptin secretion from adipose tissue. Variants near the human ADIG gene have been linked to leptin levels via genome-wide association studies, suggesting a potential genetic influence on energy balance and obesity susceptibility. No evidence currently supports Adipogenin as a receptor, enzyme, transporter, or transcription factor, and it is not a known drug target or clinical biomarker. Its primary scientific interest is in adipose biology and metabolic regulation.
- Other names
- AdipogeninADIGSmall adipocyte factor 1 (SMAF1)MGC39724RP5-1100H13.2Adipogenesis associatedSMAF1
02
Biological functions
Adipocyte differentiation/adipogenesisRegulation of leptin secretionFat mass and energy metabolism regulationAdipose tissue development
03
Disease associations
Other (association with obesity, altered leptin levels, and fat mass; not directly linked as a major driver in classic disease categories like cancer or cardiovascular disease)
04
Biomarkers
Possible: Body mass index (BMI)-adjusted leptin levels may be associated with ADIG genetic variants in GWAS, but ADIG itself is not an established biomarker
Beyond the preview
Go deeper on Adipogenin (ADIG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adipogenin (ADIG).